• ayondo

  Led · Equity · Aug 2014

  The ayondo group is a FinTech investment and operating group focused on new technologies and high-growth business models that can increase efficiency in the banking sector. Led by CEO Robert Lempka, the group has invested in innovative companies and technologies in the financial technology space since 2008. It operates a portfolio that includes social trading provider ayondo GmbH (headquartered in Frankfurt) and broker ayondo markets Ltd. (formerly Gekko Global Markets) in London. Until April 2014 the group operated under the name Next Generation Finance Invest. The company covers a broad spectrum of services in the Finance 2.0 field across both retail and institutional sectors. It recently opened a Singapore office and received an additional SGD5m investment from Singapore-based private equity group Luminor Capital to fund international expansion.

• Next Generation Finance

  Led · Equity · Jan 2014

  Next Generation Finance Invest is a Zug, Switzerland-based financial trading platform and investment company focused on electronic trading and investment platforms. Led by founding partner Robert Lempka, the firm invests in companies positioned to benefit from finance 2.0 megatrends. Its portfolio includes ayondo, Gekko Global Markets, OANDA, StockPulse, yavalu and 2iQ. Following a CHF5.5M funding round led by Singapore-based private equity firm Luminor Capital, the company will convert from an investment company into an operational holding company. It plans to delist from the BX Berne eXchange as part of that transformation. The company intends to use the proceeds to further develop the business.

• TriReme Medical

  Led · Equity · Nov 2012

  TriReme Medical is a California medical device firm with offices in Singapore that develops minimally invasive coronary and peripheral devices. Its product lineup includes the Chocolate, GliderXtreme and GliderfleX PTA balloon catheters for peripheral use and the Antares Coronary Stent system and Glider PTCA balloon catheters for coronary procedures. The company focuses on treating complex lesions and advancing next-generation interventional devices. TriReme will use the new funding to support development of its dilation catheters and to expand its commercial infrastructure globally. The company’s board includes representatives from Adams Street Partners, Three Arch Partners, Bio*One Capital and EDB Investments. CEO Eitan Konstantino said the company is "thrilled to have this major support from Asia" as it advances its device development. TriReme Medical develops, manufactures and commercializes percutaneous devices to treat complex coronary and peripheral arterial disease. The company is based in Pleasanton, California and its portfolio includes two CE marked products: the Antares® Coronary Stent System and the Glider™ PTCA Balloon Catheter. Antares is a proprietary main vessel stent designed to adapt to a broad variety of bifurcation lesions for predictable provisional stenting results. The Glider PTCA Balloon Catheter is designed to overcome limitations of conventional balloon catheters when treating complex disease. TriReme intends to use new capital to ramp up worldwide commercial activities and continue internal R&D programs. Management also plans to pursue key regulatory approvals in large markets including the US, Japan and China.

No current team members are available.